Small Molecules
21 January 2015
UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam20 January 2015
First Evidence of Potential Efficacy of Tau Aggregation Inhibitor Therapy in Alzheimer’s Disease20 January 2015
Tobira Therapeutics Doses First Subject in Phase 1 Clinical Trial of Cenicriviroc and Pioglitazone20 January 2015
Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study20 January 2015
ARIAD Announces Final Decision from European Commission Endorsing Iclusig’s Approved Indications Throughout Europe20 January 2015
Richter and Actavis Announce Positive Phase III Results for Cariprazine in the Prevention of Relapse in Patients with Schizophrenia20 January 2015
European Label Update of Bayer’s Xarelto® Now Including Guidance for Use in Patients with Atrial Fibrillation Undergoing Cardioversion19 January 2015
Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation17 January 2015
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis15 January 2015
Newron announces results of Phase I study of NW-350914 January 2015
Ascendis Pharma A/S Announces Initiation of a Phase 1 Single Ascending Dose Study of TransCon Treprostinil14 January 2015
PEGASUS-TIMI 54 study of BRILINTA® meets primary endpoint in both 60mg and 90mg doses14 January 2015
Aptose Biosciences Doses First Patient in Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies14 January 2015
MedDay provides update on pipeline progress12 January 2015
Creabilis Receives Positive Feedback on CT327 from US FDA, Providing Clear Path to Registration12 January 2015
Lipocine Announces Positive Phase 1b Top-Line Results With LPCN 1107 in Pregnant Women12 January 2015
Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Metastatic Colorectal Cancer12 January 2015
Celsus Therapeutics Announces FDA Allowance of IND for Clinical Development of MRX-6 Cream in Atopic Dermatitis12 January 2015
Global Blood Therapeutics Announces First Cohort Dosed in Phase I/II Trial of GBT440 in Sickle Cell Disease12 January 2015
Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With FebuxostatNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports